Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA07 - Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC
- 10:45 - 11:45
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
MA07.01 - Dynamic Liquid Biopsy During Immunotherapy Anticipates Hyperprogression and Early Death in Advanced Non-Small Cell Lung Cancer
10:45 - 10:50 | Presenter: Laura Bonanno
- Abstract
Loading... -
+
MA07.02 - Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150
10:50 - 10:55 | Presenter: Martin Reck
- Abstract
Loading... -
+
MA07.03 - Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2nd Line Osimertinib Treatment
10:55 - 11:00 | Presenter: Tijmen van der Wel
- Abstract
Loading... -
+
MA07.04 - Discussant
11:00 - 11:15 | Presenter: Julia K. Rotow
- Abstract
No abstract available for this presentation
-
+
MA07.05 - A Novel Blood-Based microRNA Diagnostic Test With Very High Accuracy for Early Lung Cancer Screening and Monitoring
11:15 - 11:20 | Presenter: Andrew Zhang
- Abstract
Loading... -
+
MA07.06 - Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer
11:20 - 11:25 | Presenter: Aaron C Tan
- Abstract
Loading... -
+
MA07.07 - Detecting Stage I Lung Cancer with High Sensitivity Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell Free DNA
11:25 - 11:30 | Presenter: Wei Guo
- Abstract
Loading... -
+
MA07.08 - Discussant
11:30 - 11:45 | Presenter: Chris Abbosh
- Abstract
No abstract available for this presentation
-
+
OA10 - Improving Care for People with Lung Cancer: Biomarker Testing Access, Psychosocial Distress, Care Navigation, and COVID-19 Vaccination
- 10:45 - 11:45
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Patient Advocacy
- Moderators:Andrew Ciupek
-
+
OA10.01 - Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of US-Based Oncology Clinicians
10:45 - 10:55 | Presenter: Leigh Boehmer
- Abstract
Loading... -
+
OA10.02 - Psychosocial Distress in Patients with Driver-Mutant Lung Cancer
10:55 - 11:05 | Presenter: Lia Head
- Abstract
Loading... -
+
OA10.03 - How LungMATCH, A Personalized Treatment Navigation and Clinical Trial Matching Service, Affects the Treatment Journey
11:05 - 11:15 | Presenter: Daniel Saez
- Abstract
Loading... -
+
OA10.04 - COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients
11:15 - 11:25 | Presenter: Christina Sit
- Abstract
Loading... -
+
OA10.05 - Discussant
11:25 - 11:35 | Presenter: Joshua Sabari
- Abstract
No abstract available for this presentation
-
+
OA10.06 - Live Discussion with Speakers
11:35 - 11:45
- Abstract
No abstract available for this presentation
-
+
OA11 - Early Stage NSCLC
- 10:45 - 11:45
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease/Ablative Therapies
- Moderators:Jae Kim
-
+
OA11.01 - Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer
10:45 - 10:55 | Presenter: Jair Bar
- Abstract
Loading... -
+
OA11.02 - Treatment Outcomes of Re-Irradiation Using Stereotactic Ablative Radiotherapy to Lung: A Propensity Score Matching Analysis
10:55 - 11:05 | Presenter: Tae Hoon Lee
- Abstract
Loading... -
+
OA11.03 - Oncologic Outcomes of Patients with Resected T3N0M0 Non-Small Cell Lung Cancer
11:05 - 11:15 | Presenter: Edouard Marques
- Abstract
Loading... -
+
OA11.04 - Impact of Local Control on Cause-Specific Survival After SBRT for Early-Stage NSCLC: Dynamic Prediction With Landmarking
11:15 - 11:25 | Presenter: Kazuhito Ueki
- Abstract
Loading... -
+
OA11.05 - Discussant
11:25 - 11:35 | Presenter: Pamela Samson
- Abstract
No abstract available for this presentation
-
+
OA11.06 - Live Discussion with Speakers
11:35 - 11:45
- Abstract
No abstract available for this presentation
-
+
MA08 - Driver Mutations and Immune Profiles in Early Stage NSCLC
- 12:00 - 13:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
MA08.01 - Presence of High-Grade Subtype Predicts Recurrence of Stage I Lung Adenocarcinoma Only in EGFR-Mutated Patients
12:00 - 12:05 | Presenter: Junji Ichinose
- Abstract
Loading... -
+
MA08.02 - Outcomes of Early Stage ALK-positive NSCLC Patients in a Real-World Cohort
12:05 - 12:10 | Presenter: Sabine Schmid
- Abstract
Loading... -
+
MA08.03 - Adjuvant Chemotherapy for Patients with High-Risk Stage I Lung Adenocarcinoma Stratified by Epidermal Growth Factor Receptor Mutation Status
12:10 - 12:15 | Presenter: Yasuhiro Tsutani
- Abstract
Loading... -
+
MA08.04 - Discussant
12:15 - 12:30 | Presenter: Els Wauters
- Abstract
No abstract available for this presentation
-
+
MA08.05 - Integrating Genomic and Transcriptomic Features Predict the Recurrence Risk of Stage IA Non-Small Cell Lung Cancer
12:30 - 12:35 | Presenter: Shirong Zhang
- Abstract
Loading... -
+
MA08.06 - Immune Cell Profiles as Predictors of Survival in Surgically Treated Non-Small Cell Lung Cancer (NSCLC)
12:35 - 12:40 | Presenter: Laura Sellmer
- Abstract
Loading... -
+
MA08.07 - Immune Characteristics Associated With Lymph Node Metastasis in Early-Stage NSCLC Discovered via T Cell Receptor Repertoires Sequencing
12:40 - 12:45 | Presenter: Min Li
- Abstract
Loading... -
+
MA08.08 - Discussant
12:45 - 13:00 | Presenter: Keiju Aokage
- Abstract
No abstract available for this presentation
-
+
OA12 - Understanding and Augmenting Responses to Immunotherapy for Thoracic Malignancies
- 12:00 - 13:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
- Moderators:Valsamo Anagnostou
-
+
OA12.01 - Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma
12:00 - 12:10 | Presenter: Valsamo Anagnostou
- Abstract
Loading... -
+
OA12.02 - Metformin Has Divergent Effects on the Tumor Immune Microenvironment of Non-Small Cell Lung Cancer (NSCLC) Depending on Obesity
12:10 - 12:20 | Presenter: Joseph Barbi
- Abstract
Loading... -
+
OA12.03 - Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC
12:20 - 12:30 | Presenter: Shuai Li
- Abstract
Loading... -
+
OA12.04 - Pre-Treatment T-Cell Receptors (TCR) Repertoire in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Single Agent Immunotherapy
12:30 - 12:40 | Presenter: Afaf Abed
- Abstract
Loading... -
+
OA12.05 - Discussant
12:40 - 12:50 | Presenter: David Carbone
- Abstract
No abstract available for this presentation
-
+
OA12.06 - Live Discussion with Speakers
12:50 - 13:00
- Abstract
No abstract available for this presentation
-
+
IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape with Novel Strategies
- 13:15 - 14:15
- 9/09/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
- Moderators:David R. Gandara, Alexander Spira, Afshin Dowlati
-
+
IS05.01 - Welcome and Introductions
13:15 - 13:20 | Presenter: David R. Gandara
- Abstract
No abstract available for this presentation
-
+
IS05.02 - The Evolving Biomarker Landscape in Advanced NSCLC
13:20 - 13:35 | Presenter: David R. Gandara
- Abstract
No abstract available for this presentation
-
+
IS05.03 - KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC
13:35 - 13:50 | Presenter: Alexander Spira
- Abstract
No abstract available for this presentation
-
+
IS05.04 - Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC
13:50 - 14:05 | Presenter: Afshin Dowlati
- Abstract
No abstract available for this presentation
-
+
IS05.05 - Discussion
14:05 - 14:15
- Abstract
No abstract available for this presentation
-
+
IS06 - Industry Symposium Sponsored by Jazz Pharmaceuticals: Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC)
- 13:15 - 14:15
- 9/09/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS06.01 - An Overview of Unmet Needs in SCLC
13:15 - 13:30 | Presenter: Eric Nadler
- Abstract
No abstract available for this presentation
-
+
IS06.02 - Current Treatment Guidelines for SCLC
13:30 - 13:45 | Presenter: Eric Nadler
- Abstract
No abstract available for this presentation
-
+
IS06.03 - Efficacy and Safety Findings from a Study of an FDA-Approved Treatment for Previously Treated Metastatic SCLC
13:45 - 14:00 | Presenter: Eric Nadler
- Abstract
No abstract available for this presentation
-
+
IS06.04 - Considerations for Dosing, Administration, and Patient Counseling
14:00 - 14:15 | Presenter: Eric Nadler
- Abstract
No abstract available for this presentation
-
+
IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC
- 13:15 - 14:15
- 9/09/2021
- Location: Program Auditorium
- CME Accredited by Other Provider
- Type: Satellite CME Symposia
- Track: N.A.
-
+
IS07.01 - Introduction
13:15 - 13:20 | Presenter: Roy Herbst
- Abstract
No abstract available for this presentation
-
+
IS07.02 - Key Concepts in NSCLC Biomarker Testing
13:20 - 13:35 | Presenter: Aleš Ryška
- Abstract
No abstract available for this presentation
-
+
IS07.03 - Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC
13:35 - 13:55 | Presenter: Roy Herbst
- Abstract
No abstract available for this presentation
-
+
IS07.04 - IRAE Considerations for Patients with NSCLC Receiving Immunotherapy
13:55 - 14:05 | Presenter: Sarah B Goldberg
- Abstract
No abstract available for this presentation
-
+
IS07.05 - Live Q&A
14:05 - 14:15
- Abstract
No abstract available for this presentation
-
+
PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)
- 14:30 - 16:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02A.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
14:30 - 14:40 | Presenter: Melissa L Johnson
- Abstract
Loading... -
+
PL02A.02 - Discussant
14:40 - 14:47 | Presenter: Julie Brahmer
- Abstract
No abstract available for this presentation
-
+
PL02A.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
14:47 - 14:57 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
PL02A.04 - Discussant
14:57 - 15:04 | Presenter: Charles M Rudin
- Abstract
No abstract available for this presentation
-
+
PL02A.05 - IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
15:04 - 15:14 | Presenter: Nasser Altorki
- Abstract
Loading... -
+
PL02A.06 - Discussant
15:14 - 15:21 | Presenter: Ichiro Yoshino
- Abstract
No abstract available for this presentation
-
+
PL02A.07 - Global Variability in Lung Cancer Deaths Attributable to Air Pollution
15:21 - 15:31 | Presenter: Christine Dorothy Berg
- Abstract
Loading... -
+
PL02A.08 - Discussant
15:31 - 15:38 | Presenter: Joachim G.J.V. Aerts
- Abstract
No abstract available for this presentation
-
+
PL02A.09 - International Association for the Study of Lung Cancer (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical Trials
15:38 - 15:48 | Presenter: Matthew Smeltzer
- Abstract
Loading... -
+
PL02A.10 - Discussant
15:48 - 15:55 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
PL02A.11 - Live Discussion with Speakers
15:55 - 16:00
- Abstract
No abstract available for this presentation